Promoter context determines the role of proteasome in ligand-dependent occupancy of retinoic acid responsive elements

Epigenetics

Volumn 6, Issue 2, 2011, Pages 202-211

  Higazi, Aliaa ^a   Abed, Mahmoud ^a   Chen, Jihong ^a   Li, Qiao ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Gene regulation; Genomic association; Nuclear receptor; The 26S proteasome; Transcriptional coactivator

Indexed keywords

26S PROTEASOME; GENOMIC DNA; LIGAND; PROTEASOME; PROTEIN P300; REGULATOR PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DNA STRUCTURE; EMBRYO; MOUSE; NONHUMAN; PROMOTER REGION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RETINOIC ACID RESPONSIVE ELEMENT;

EID: 79951487652     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.2.13658     Document Type: Article

References (56)

1. Niederreither K, Dolle P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008; 9:541-53.
2. Wilson JG, Roth CB, Warkany J. An analysis of the syndrome of malformations induced by maternal vitamin A deficiency. Effects of restoration of vitamin A at various times during gestation. Am J Anat 1953; 92:189-217.
3. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10:940-54.
4. Lonard DM, O'Malley BW. Nuclear receptor coregulators: judges, juries and executioners of cellular regulation. Mol Cell 2007; 27:691-700.
5. Chambon P. The nuclear receptor superfamily: a personal retrospect on the first two decades. Mol Endocrinol 2005; 19:1418-28.
6. Folkers GE, van der Burg B, van der Saag PT. Promoter architecture, cofactors and orphan receptors contribute to cell-specific activation of the retinoic acid receptor beta2 promoter. J Biol Chem 1998; 273:32200-12.
7. Pavri R, Lewis B, Kim TK, Dilworth FJ, Erdjument-Bromage H, Tempst P, et al. PARP-1 determines specificity in a retinoid signaling pathway via direct modulation of mediator. Mol Cell 2005; 18:83-96.
8. Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. Nature 1995; 374:81-4.
9. Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 1996; 87: 953-9.
10. Torchia J, Glass C, Rosenfeld MG. Co-activators and co-repressors in the integration of transcriptional responses. Curr Opin Cell Biol 1998; 10:373-83.
11. Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence JB, et al. Molecular cloning and functional analysis of the adenovirus E1Aassociated 300 kD protein (p300) reveals a protein with properties of a transcriptional adaptor. Genes Dev 1994; 8:869-84.
12. Yao TP, Oh SP, Fuchs M, Zhou ND, Ch'ng LE, Newsome D, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93: 361-72.
13. Muraoka M, Konishi M, Kikuchi-Yanoshita R, Tanaka K, Shitara N, Chong JM, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12:1565-9.
14. Gayther SA, Batley SJ, Linger L, Bannister A, Thorpe K, Chin SF, et al. Mutations truncating the EP300 acetylase in human cancers. Nat Genet 2000; 24:300-3.
15. Suganuma T, Kawabata M, Ohshima T, Ikeda MA. Growth suppression of human carcinoma cells by reintroduction of the p300 coactivator. Proc Natl Acad Sci USA 2002; 99:13073-8.
16. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8:397-403.
17. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999; 96:1858-62.
18. Lange CA, Shen T, Horwitz KB. Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. Proc Natl Acad Sci USA 2000; 97:1032-7.
19. Molinari E, Gilman M, Natesan S. Proteasomemediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J 1999; 18:6439-47.
20. Lonard DM, Nawaz Z, Smith CL, O'Malley BW. The 26S proteasome is required for estrogen receptoralpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol Cell 2000; 5:939-48.
21. Poizat C, Sartorelli V, Chung G, Kloner RA, Kedes L. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol Cell Biol 2000; 20:8643-54.
22. Gianni M, Kopf E, Bastien J, Oulad-Abdelghani M, Garattini E, Chambon P, et al. Downregulation of the phosphatidylinositol 3-kinase/Akt pathway is involved in retinoic acid-induced phosphorylation, degradation and transcriptional activity of retinoic acid receptorgamma2. J Biol Chem 2002; 277:24859-62.
23. Kopf E, Plassat JL, Vivat V, de The H, Chambon P, Rochette-Egly C. Dimerization with retinoid X receptors and phosphorylation modulate the retinoic acidinduced degradation of retinoic acid receptors alpha and gamma through the ubiquitin-proteasome pathway. J Biol Chem 2000; 275:33280-8.
24. Li Q, Su A, Chen J, Lefebvre YA, Hache RJ. Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. Mol Endocrinol 2002; 16:2819-27.
25. Chen J, St-Germain JR, Li Q. B56 regulatory subunit of protein phosphatase 2A mediates valproic acid-induced p300 degradation. Mol Cell Biol 2005; 25:525-32.
26. Chen J, Halappanavar S, Th'ng JP, Li Q. Ubiquitindependent distribution of the transcriptional coactivator p300 in cytoplasmic inclusion bodies. Epigenetics 2007; 2:92-9.
27. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17:7151-60.
28. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49:73-96.
29. Dembla-Rajpal N, Seipelt R, Wang Q, Rymond BC. Proteasome inhibition alters the transcription of multiple yeast genes. Biochim Biophys Acta 2004; 1680:34-45.
30. Salghetti SE, Caudy AA, Chenoweth JG, Tansey WP. Regulation of transcriptional activation domain function by ubiquitin. Science 2001; 293:1651-3.
31. Ferdous A, Gonzalez F, Sun L, Kodadek T, Johnston SA. The 19S regulatory particle of the proteasome is required for efficient transcription elongation by RNA polymerase II. Mol Cell 2001; 7:981-91.
32. Perissi V, Aggarwal A, Glass CK, Rose DW, Rosenfeld MG. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116:511-26.
33. Bissonnette RP, Brunner T, Lazarchik SB, Yoo NJ, Boehm MF, Green DR, et al. 9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Mol Cell Biol 1995; 15:5576-85.
34. McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ. Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature 1982; 299:165-7.
35. Deroo BJ, Rentsch C, Sampath S, Young J, DeFranco DB, Archer TK. Proteasomal inhibition enhances glucocorticoid receptor transactivation and alters its subnuclear trafficking. Mol Cell Biol 2002; 22:4113-23.
36. Obrig TG, Culp WJ, McKeehan WL, Hardesty B. The mechanism by which cycloheximide and related glutarimide antibiotics inhibit peptide synthesis on reticulocyte ribosomes. J Biol Chem 1971; 246:174-81.
37. Kao HY, Han CC, Komar AA, Evans RM. Co-repressor release but not ligand binding is a prerequisite for transcription activation by human retinoid acid receptoralpha ligand-binding domain. J Biol Chem 2003; 278:7366-73.
38. Loudig O, Maclean GA, Dore NL, Luu L, Petkovich M. Transcriptional co-operativity between distant retinoic acid response elements in regulation of Cyp26A1 inducibility. Biochem J 2005; 392:241-8.
39. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7:9-16.
40. Nawaz Z, O'Malley BW. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription? Mol Endocrinol 2004; 18:493-9.
41. Verma S, Ismail A, Gao X, Fu G, Li X, O'Malley BW, et al. The ubiquitin-conjugating enzyme UBCH7 acts as a coactivator for steroid hormone receptors. Mol Cell Biol 2004; 24:8716-26.
42. Chen ZJ, Sun LJ. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009; 33:275-86.
43. Dace A, Zhao L, Park KS, Furuno T, Takamura N, Nakanishi M, et al. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 2000; 97:8985-90.
44. Tanaka T, Rodriguez de la Concepcion ML, De Luca LM. Involvement of all-trans-retinoic acid in the breakdown of retinoic acid receptors alpha and gamma through proteasomes in MCF-7 human breast cancer cells. Biochem Pharmacol 2001; 61:1347-55.
45. Andela VB, Rosier RN. The proteosome inhibitor MG132 attenuates retinoic acid receptor trans-activation and enhances trans-repression of nuclear factor kappaB. Potential relevance to chemo-preventive interventions with retinoids. Mol Cancer 2004; 3:8.
46. Gianni M, Bauer A, Garattini E, Chambon P, Rochette-Egly C. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. EMBO J 2002; 21:3760-9.
47. Salghetti SE, Muratani M, Wijnen H, Futcher B, Tansey WP. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc Natl Acad Sci USA 2000; 97:3118-23.
48. Ferdous A, Sikder D, Gillette T, Nalley K, Kodadek T, Johnston SA. The role of the proteasomal ATPases and activator monoubiquitylation in regulating Gal4 binding to promoters. Genes Dev 2007; 21:112-23.
49. Lee D, Ezhkova E, Li B, Pattenden SG, Tansey WP, Workman JL. The proteasome regulatory particle alters the SAGA coactivator to enhance its interactions with transcriptional activators. Cell 2005; 123:423-36.
50. Perlmann T, Rangarajan PN, Umesono K, Evans RM. Determinants for selective RAR and TR recognition of direct repeat HREs. Genes Dev 1993; 7:1411-22.
51. Depoix C, Delmotte MH, Formstecher P, Lefebvre P. Control of retinoic acid receptor heterodimerization by ligand-induced structural transitions. A novel mechanism of action for retinoid antagonists. J Biol Chem 2001; 276:9452-9.
52. Zechel C, Shen XQ, Chambon P, Gronemeyer H. Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements. EMBO J 1994; 13:1414-24.
53. Chen J, Halappanavar SS, St-Germain JR, Tsang BK, Li Q. Role of Akt/protein kinase B in the activity of transcriptional coactivator p300. Cell Mol Life Sci 2004; 61:1675-83.
54. Chen J, Ghazawi FM, Bakkar W, Li Q. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 2006; 5:71.
55. Lefebvre B, Brand C, Lefebvre P, Ozato K. Chromosomal integration of retinoic acid response elements prevents cooperative transcriptional activation by retinoic acid receptor and retinoid X receptor. Mol Cell Biol 2002; 22:1446-59.
56. Gillespie RF, Gudas LJ. Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2) and Cyp26A1 in F9 embryonal carcinoma cells. J Mol Biol 2007; 372:298-316.